Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J01DE51

Exblifep(cefepime dihydrochloride monohydrate;Enmetazobactam)

Urinary Tract Infections;Pyelonephritis;Healthcare-Associated Pneumonia;Pneumonia, Ventilator-Associated

Marketing Authorisation Holder: Advanz Pharma Limited

EMA Authorisation: 21/03/2024

INN: cefepime;enmetazobactam

Indication

Exblifep is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1): - Complicated urinary tract infections (cUTI), including pyelonephritis - Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Exblifep — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.